Mecasermin (IGF-1) trial to evaluate safety and efficacy in post-heart attack patients

Following a heart attack, a blocked coronary artery can lead to weakened heart muscle and subsequent heart failure. Current standard-of-care focuses on restoring blood flow, but often doesn't fully prevent long-term cardiac damage. The body naturally produces insulin-like growth factor-1 (IGF-1), a protein known for its potential to protect heart muscle cells from dying and mitigate damage. This inherent protective mechanism suggests that exogenous IGF-1, available as the drug mecasermin, could offer a novel therapeutic strategy to preserve cardiac function and prevent post-infarction heart failure.

This study is designed as a randomized, placebo-controlled clinical trial. Heart attack patients who have undergone successful coronary artery re-opening via stent will be enrolled. Participants will receive either a dose of mecasermin or a placebo (inactive treatment) post-procedure. The primary objective is to evaluate the safety of mecasermin therapy. Efficacy will be assessed by testing if the therapy can prevent or lessen heart failure, with outcomes measured using cardiac magnetic resonance imaging (MRI) taken one day and eight weeks after the heart attack. This design directly compares the investigational treatment against a control to determine its impact on cardiac recovery.

This study is a clinical trial design, and as such, no efficacy or safety results are yet available. The primary aim is to rigorously evaluate the safety profile of mecasermin when administered to heart attack patients post-stenting. Furthermore, the trial will test the hypothesis that mecasermin can prevent or significantly lessen the development of heart failure following myocardial infarction. The key measurement for cardiac function and damage will be cardiac magnetic resonance imaging (MRI), which will be performed at two critical time points: one day and eight weeks after the acute event. The comparison between the mecasermin group and the placebo group on these MRI parameters will provide crucial data on the therapeutic potential.

The central goal is to determine if mecasermin can preserve heart muscle and prevent the progression to heart failure in a vulnerable patient population.